ASCO cont – responses to anti-PD-1 including retreatment

› Forums › General Melanoma Community › ASCO cont – responses to anti-PD-1 including retreatment

  • Post
Viewing 1 reply thread
  • Replies
      • June 27, 2019 at 11:53 pm
      Johnjk04
      Participant
        Many thanks for the results Les. Marvelous to have all of your insight as well.
        • June 28, 2019 at 2:08 pm
        ed williams
        Participant
          Hi Celeste, I agree with your feelings about the retrospective design including one treatment folks!!! The data does make one think that if a pd-1 patients needs future treatment due to progression after stopping treatment, that clinical trials or Ipi+nivo combination might be better choice than using pd-1 monotherapy a second time!!!!Best Wishes!!!Ed
            • June 28, 2019 at 5:13 pm
            Bubbles
            Participant
              I agree!!! c
        Viewing 1 reply thread
        • You must be logged in to reply to this topic.
        About the MRF Patient Forum

        The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

        The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

        Popular Topics